Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study.
Igawa S, Ono T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S, Nishinarita N, Fukui T, Kubota M, Sasaki J, Hisashi M, Yokoba M, Katagiri M, Naoki K. Igawa S, et al. Among authors: nishinarita n. Cancer Manag Res. 2019 May 28;11:4883-4892. doi: 10.2147/CMAR.S207170. eCollection 2019. Cancer Manag Res. 2019. PMID: 31213907 Free PMC article.
Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
Igawa S, Shirasawa M, Ozawa T, Nishinarita N, Okuma Y, Ono T, Sugimoto A, Kurahayashi S, Sugita K, Sone H, Fukui T, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K. Igawa S, et al. Among authors: nishinarita n. Thorac Cancer. 2018 Aug;9(8):967-973. doi: 10.1111/1759-7714.12772. Epub 2018 Jun 5. Thorac Cancer. 2018. PMID: 29870153 Free PMC article.
Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease.
Igawa S, Nishinarita N, Takakura A, Ozawa T, Harada S, Kusuhara S, Niwa H, Hosotani S, Sone H, Nakahara Y, Fukui T, Mitsufuji H, Yokoba M, Kubota M, Katagiri M, Sasaki J, Naoki K. Igawa S, et al. Among authors: nishinarita n. Cancer Manag Res. 2018 Dec 14;10:7013-7019. doi: 10.2147/CMAR.S189556. eCollection 2018. Cancer Manag Res. 2018. PMID: 30588105 Free PMC article.
Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study.
Ono T, Igawa S, Ozawa T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S, Nishinarita N, Fukui T, Kubota M, Sasaki J, Hisashi M, Katagiri M, Naoki K. Ono T, et al. Among authors: nishinarita n. Thorac Cancer. 2019 Apr;10(4):880-889. doi: 10.1111/1759-7714.13018. Epub 2019 Feb 28. Thorac Cancer. 2019. PMID: 30821083 Free PMC article.
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Igawa S, Shirasawa M, Fukui T, Nishinarita N, Sone H, Ozawa T, Sugita K, Okuma Y, Kurahayashi S, Ono T, Sugimoto A, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K. Igawa S, et al. Among authors: nishinarita n. Oncology. 2018;94(4):207-214. doi: 10.1159/000486038. Epub 2018 Jan 31. Oncology. 2018. PMID: 29393275
Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer.
Shirasawa M, Fukui T, Kusuhara S, Harada S, Nishinarita N, Hiyoshi Y, Ishihara M, Kasajima M, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K. Shirasawa M, et al. Among authors: nishinarita n. PLoS One. 2019 Apr 19;14(4):e0214599. doi: 10.1371/journal.pone.0214599. eCollection 2019. PLoS One. 2019. PMID: 31002722 Free PMC article.